SCHEMBL13140331

SCHEMBL13140331

Cc1cc(-c2cccc(C)c2C)c(C)cc1OCCC(C)(C)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 2/20 0.42
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ HTR1B P28222 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ GAA P10253 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ TSHR P16473 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ TTR P02766 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C8 P10632 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ SLCO1B3 Q9NPD5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13117512 0.87 VDR (0.44) VDRTSHRTDP1TTRCYP1A2
SCHEMBL13117432 0.83 MAPT (0.41) VDRMAPTGAAKDM4ETSHR
SCHEMBL13213376 0.83 VDR (0.36) VDRMAPTTSHRTDP1TTR
SCHEMBL13139887 0.81 CNR1 (0.41) CNR1CNR2MAPTTDP1PPARG
SCHEMBL13140334 0.78 CNR1 (0.36) VDRCNR1CNR2MAPTGAA
SCHEMBL13117715 0.78 CD274 (0.40) KDM4EPDCD1CD274
SCHEMBL12569627 0.73 VDR (0.48) VDRMAPTGAAKDM4ETSHR
SCHEMBL13139842 0.72 CNR1 (0.36) VDRCNR1CNR2MAPTTDP1
SCHEMBL13139845 0.71 CD274 (0.50) RARBS1PR1PDCD1CD274
SCHEMBL13117528 0.69 CD274 (0.44) VDRIDO1S1PR1PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 VDR 158/4885CNR1 523/4885CNR2 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback